Morgan Stanley set a $100.00 price target on CVS Health (NYSE:CVS) in a research report sent to investors on Wednesday, The Fly reports. The firm currently has a buy rating on the pharmacy operator’s stock.

CVS has been the topic of a number of other research reports. Royal Bank of Canada set a $99.00 target price on shares of CVS Health and gave the company a buy rating in a research report on Tuesday, October 23rd. Bank of America boosted their target price on shares of CVS Health from $86.00 to $90.00 and gave the company a buy rating in a research report on Monday, September 17th. ValuEngine upgraded shares of CVS Health from a strong sell rating to a sell rating in a research report on Tuesday, August 28th. Tigress Financial reiterated a buy rating on shares of CVS Health in a research report on Friday, October 26th. Finally, Wolfe Research started coverage on shares of CVS Health in a research report on Thursday, October 25th. They set a peer perform rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of $89.38.

Shares of CVS Health stock traded down $0.22 during trading on Wednesday, reaching $79.83. 5,761,328 shares of the company traded hands, compared to its average volume of 8,350,557. The company has a quick ratio of 1.87, a current ratio of 2.44 and a debt-to-equity ratio of 1.66. CVS Health has a 1-year low of $60.14 and a 1-year high of $83.88. The company has a market capitalization of $80.25 billion, a PE ratio of 13.53, a PEG ratio of 1.05 and a beta of 0.98.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.71 by $0.02. CVS Health had a net margin of 1.65% and a return on equity of 18.69%. The company had revenue of $47.27 billion for the quarter, compared to the consensus estimate of $47.22 billion. During the same quarter in the previous year, the company earned $1.50 EPS. CVS Health’s quarterly revenue was up 2.4% compared to the same quarter last year. Sell-side analysts expect that CVS Health will post 7.04 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Wednesday, October 24th were paid a dividend of $0.50 per share. The ex-dividend date was Tuesday, October 23rd. This represents a $2.00 dividend on an annualized basis and a yield of 2.51%. CVS Health’s dividend payout ratio (DPR) is presently 33.90%.

In other CVS Health news, EVP Eva C. Boratto sold 13,311 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the completion of the sale, the executive vice president now owns 55,162 shares in the company, valued at approximately $4,256,299.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Lisa Bisaccia sold 21,534 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $80.00, for a total transaction of $1,722,720.00. The disclosure for this sale can be found here. Insiders have sold a total of 43,409 shares of company stock valued at $3,392,097 in the last 90 days. 0.53% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the business. Camarda Financial Advisors LLC bought a new stake in shares of CVS Health in the 2nd quarter worth $102,000. Kiley Juergens Wealth Management LLC bought a new stake in shares of CVS Health in the 2nd quarter worth $103,000. Legacy Advisors LLC grew its stake in shares of CVS Health by 7,100.0% in the 2nd quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock worth $116,000 after acquiring an additional 1,775 shares in the last quarter. Squar Milner Financial Services LLC bought a new stake in shares of CVS Health in the 2nd quarter worth $122,000. Finally, Canton Hathaway LLC bought a new stake in shares of CVS Health in the 3rd quarter worth $126,000. Institutional investors and hedge funds own 82.42% of the company’s stock.

About CVS Health

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Further Reading: S&P 500 Index

The Fly

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.